Local drugmakers dominate in segment of vital drugs in Russia

The share of domestic drugs in the list of vital drugs available in the Russian pharmaceutical market in 2017 reached a record high of 84% for the last 20 years, according to recent statements of the Russian Minister of Industry and Trade Denis Manturov and some senior officials of the Ministry of Health, reports The Pharma Letter’s local correspondent.

Analysts predict the growth will continue this year, which may result in the increase of this figure up to 90% by the end of 2018. They also predict this will also result in a further decline of prices in the Russian market. In comparison, in 2012 only 63.5% of drugs from the list of vital in Russia were produced domestically.

Viktor Dmitriev, head of the Association of Russian Pharmaceutical Manufacturers of Russia, which unites domestic and foreign drugmakers, operating in the country, said that the increase in the share was mainly achieved due to a significant deepening of localization of drugs by foreign drugmakers which has been observed in Russia in recent years.